Shiga, Japan-The improvement of interstitial cystitis symptoms with a still-investigational oral agent correlates well with a reduction in bladder platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) expression, suggesting the agent's potential for treating symptoms in patients with nonulcerative IC.
